Coffey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, Sadiq SA,
Turner MS. Abrupt withdrawal from intrathecal baclofen: recognition and management of a …

Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that
predominantly affects white matter. MS has a variable clinical presentation and has no ‘diagnostic’ …

Multiple sclerosis (MS) is an autoimmune disease of unknown cause, in which chronic
inflammation drives multifocal demyelination of axons in both white and gray matter in the CNS. …

Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is
associated with chronic inflammation leading to demyelination and neurodegeneration. With …

Background Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the
central nervous system and is one of the leading causes of disability in young adults. Cell …

Multiple sclerosis (MS) is associated with irreversible disability in a significant proportion of
patients. At present, there is no treatment to halt or reverse the progression of established …

Background Intrathecal baclofen (ITB) is an effective treatment for severe spasticity. In
ambulatory patients with spasticity, it is possible that ITB treatment may compromise ambulatory …

Bone marrow mesenchymal stem cell-derived neural progenitors (MSC-NPs) are a potential
therapeutic source of cells that have been shown to be efficacious in a preclinical model of …

Immunocompromised individuals, including multiple sclerosis (MS) patients on certain
immunotherapy treatments, are considered susceptible to complications from severe acute …

Background aims There is a critical unmet need to develop regenerative therapies for the
demyelinating disease multiple sclerosis (MS). We previously characterized the …